Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Damien Reita, L. Pabst, Erwan Pencreach, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1321-1321
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies
Behnam Najafiyan, Zahra Bokaii Hosseini, Samar Esmaelian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116207-116207
Open Access | Times Cited: 22
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
William H. Gmeiner
Cancers (2024) Vol. 16, Iss. 5, pp. 1029-1029
Open Access | Times Cited: 17
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Yunkai Yang, Huan Zhang, Shanshan Huang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 709-709
Open Access | Times Cited: 27
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
Pankaj Garg, Sulabh Singhal, Prakash Kulkarni, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4189-4189
Open Access | Times Cited: 10
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Zixi Wang, Yurou Xing, Bingjie Li, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 31
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer
Kelsey Pan, Kyle Concannon, Jing Li, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 716-732
Closed Access | Times Cited: 20
Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target
Amar Ajmal, Hind A. Alkhatabi, Roaa M. Alreemi, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 5
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
Tämer El Saadany, Judith E. Lupatsch, Michael Mark, et al.
Schweizerische medizinische Wochenschrift (2025) Vol. 155, Iss. 1, pp. 3777-3777
Open Access
HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms
Shruti Ghai, Rejina Shrestha, Kuo‐Hui Su
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access
Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC
S. Mukherjee, Dhananjay Suresh, Ajit Zambre, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 490-490
Open Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations
S. Mohammed Zaidh, Hariharan Thirumalai Vengateswaran, Mohammad Habeeb, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Emerging Targets in Non-Small Cell Lung Cancer
Louisa Liu, Joshua Soler, Karen L. Reckamp, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10046-10046
Open Access | Times Cited: 4
Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway
Xuenan Hou, Chishun Zhou, Zuhui Liang, et al.
Phytomedicine (2023) Vol. 121, pp. 155093-155093
Open Access | Times Cited: 10
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Parth Malik, Ruma Rani, Raghu Solanki, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 850-895
Open Access | Times Cited: 10
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
Ali Chour, Anne‐Claire Toffart, E. Berton, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Does artificial intelligence need companionship to assist in drug discovery? The Kirsten rat sarcoma virus study
Mourad Stitou, John M. Koomen, Denis Imbody, et al.
Deleted Journal (2024) Vol. 1, Iss. 1
Open Access | Times Cited: 2
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors
Jelena Dinić, Miodrag Dragoj, Sofija Jovanović Stojanov, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1984-1984
Open Access | Times Cited: 2
Research progress on the use of Salvia miltiorrhiza Bunge extracts in the treatment of pulmonary diseases
Peifeng Huang, Xuezhen Wang, Yingyi Cao, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117282-117282
Open Access | Times Cited: 2
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Min Tang, Yijun Wu, Xiufeng Bai, et al.
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 683-695
Open Access | Times Cited: 2
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer
David Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Lung Cancer (2024) Vol. 197, pp. 107964-107964
Closed Access | Times Cited: 2
Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
Christophe Bontoux, Véronique Hofman, Patrick Brest, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1628-1628
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top